Evaluation of chromosome 17 polysomy in breast cancer by FISH analysis of whole nuclei, and its clinicopathological significance

Human epidermal growth factor receptor 2 (HER2) amplification and overexpression are associated with poor prognosis and resistance to cytotoxic drugs in patients with breast cancer. Increases in the number of HER2 gene copies have been shown to be associated with chromosome 17 polysomy. The use of whole, intact nuclei for fluorescence in situ hybridization (FISH) assay improves the accuracy of the results. FISH analysis of whole nuclei (WNFISH) and immunohistochemistry (IHC) were used to analyze HER2 gene amplification and HER2 protein expression in 109 breast cancer specimens. Chromosome 17 polysomy and its correlations with HER2 gene amplification, HER2 protein expression and the clinicopathological outcomes of the patients were also investigated. Among the 109 cases, WNFISH detected HER2 amplification in 30 cases, equivocal amplification in 19 cases and no amplification in 60 cases. WNFISH detected chromosome 17 centromere (CEP17) polysomy in 37 cases and no polysomy in 72 cases. Among the 109 cases assessed by tissue microarray and IHC, 31 cases were HER2-negative, 14 cases were scored 1+, 23 cases were scored 2+ and 41 cases were scored 3+. The results demonstrated that in the cases with chromosome 17 polysomy, the HER2 gene was amplified, HER2 protein expression was increased and the incidences of nuclear atypia and lymph node metastases were higher compared with those in the cases without chromosome 17 polysomy. Chromosome 17 polysomy may correlate with increased malignant potential and metastatic spread in breast cancer.

[1]  Liyan Wan,et al.  Thyroid Transcription Factor-1 Amplification and Expressions in Lung Adenocarcinoma Tissues and Pleural Effusions Predict Patient Survival and Prognosis , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  L. Goldstein,et al.  Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Wei Zhang,et al.  The Important Molecular Markers on Chromosome 17 and Their Clinical Impact in Breast Cancer , 2011, International journal of molecular sciences.

[4]  E. Perez,et al.  Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. , 2009, The Lancet. Oncology.

[5]  Patrick Neven,et al.  Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Rosenberg.  Polysomy 17 and HER-2 amplification: true, true, and unrelated. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  C. Sotiriou,et al.  Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer , 2006, Molecular Cancer Therapeutics.

[8]  T. Zhao,et al.  A New Method to Make Nuclei or Cell Microarrays , 2006, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[9]  P. Klein,et al.  Concordance between central and local laboratory HER2 testing from a community-based clinical study. , 2006, Clinical breast cancer.

[10]  Irene L Andrulis,et al.  HER2 and responsiveness of breast cancer to adjuvant chemotherapy. , 2006, The New England journal of medicine.

[11]  T. Grogan,et al.  The Influence of Polysomy 17 on HER2 Gene and Protein Expression in Adenocarcinoma of the Breast: A Fluorescent In Situ Hybridization, Immunohistochemical, and Isotopic mRNA In Situ Hybridization Study , 2005, The American journal of surgical pathology.

[12]  C. Sotiriou,et al.  Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice , 2005, Clinical Cancer Research.

[13]  M. Risio,et al.  HER2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment. , 2005, Oncology reports.

[14]  A. Ullrich,et al.  The discovery of receptor tyrosine kinases: targets for cancer therapy , 2004, Nature Reviews Cancer.

[15]  C. Cohen,et al.  Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. , 2003, Human pathology.

[16]  M. Ladanyi,et al.  Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification. , 2003, The Journal of molecular diagnostics : JMD.

[17]  P. N. Rao,et al.  Her‐2/neu Gene Amplification in Low to Moderately Expressing Breast Cancers: Possible Role of Chromosome 17/Her‐2/neu Polysomy , 2001, The breast journal.

[18]  M. Gnant,et al.  Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  D. Treré,et al.  c‐erbB‐2 over‐expression in amplified and non‐amplified breast carcinoma samples , 1999, International journal of cancer.

[20]  T. Yamamoto,et al.  The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. , 1986, Science.

[21]  F. O'Malley,et al.  Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial , 2011, Breast Cancer Research and Treatment.

[22]  J. Thigpen.  HER2, TOP2A, and TIMP-1 and Responsiveness to Adjuvant Anthracycline-Containing Chemotherapy in High-Risk Breast Cancer Patients , 2011 .

[23]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.

[24]  J. Bartlett,et al.  Chromosome 17 Aneusomy is Associated with Poor Prognostic Factors in Invasive Breast Carcinoma , 2004, Breast Cancer Research and Treatment.

[25]  R. Alsabeh,et al.  Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. , 2004, American journal of clinical pathology.

[26]  K McPherson,et al.  ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. , 2000, BMJ.